Resource investment focused on autologous cell therapy and collaboration in the allogeneic cell therapy field
First written in FY2019. 3 of 4 entries say "Restated". Latest entry: FY2022.
No other company in this theme has enough history to compare yet.
- FY2022RestatedAnnual report
「Leveraging its close relationships with partner medical institutions as a strength, the company will invest resources primarily in autologous cell therapies and exosome-related treatment and development. In the allogeneic cell therapy field, it will collaborate as a raw-material supplier with other companies that manufacture regenerative medicine products.」
The policy of prioritizing investment in autologous cells and exosomes and collaborating as a raw-material supplier in the allogeneic cell field continues. - FY2021RestatedAnnual report
「Leveraging its close relationships with partner medical institutions as a strength, the company will invest resources primarily in autologous cell therapies and exosome-related treatment and development. In the allogeneic cell therapy field, it will collaborate as a raw-material supplier with other companies that manufacture regenerative medicine products.」
The policy of prioritizing investment in autologous cells and exosomes and collaborating as a raw-material supplier in the allogeneic cell field continues. - FY2020RestatedAnnual report
「Leveraging its close relationships with partner medical institutions as a strength, the company will invest resources primarily in autologous cell therapies and exosome-related treatment and development. In the allogeneic cell therapy field, it will collaborate as a raw-material supplier with other companies that manufacture regenerative medicine products.」
The policy of prioritizing investment in autologous cells and exosomes and collaborating as a raw-material supplier in the allogeneic cell field continues. - FY2019First statedAnnual report
「Leveraging its close relationships with partner medical institutions as a strength, the company will invest resources primarily in autologous cell therapies and exosome-related treatment and development. In the allogeneic cell therapy field, which is subject to intense competition, the company will generally not enter the market itself, but will collaborate as a raw-material supplier with other companies that manufacture regenerative medicine products using allogeneic cell materials.」
The company distinguishes between its handling of autologous and allogeneic cells, specifying priority investment in the former and raw-material supply in the latter.